Sandeep Seth to exit Pfizer as Senior Director - Compliance
Mumbai: Pfizer has announced that Sandeep Seth, Senior Director - Compliance, has tendered his resignation from the services of the Company.
His departure will be effective from the close of business hours on May 13, 2025, as he plans to pursue opportunities outside Pfizer Limited.
Following his resignation, Sandeep Seth shall accordingly cease to be a Senior Management Personnel at Pfizer, marking the end of his tenure with the pharmaceutical giant.
With over 20 years of experience in Compliance, Regulatory Affairs, Legal, and Operations, Seth has been a significant contributor to the industry. His career spans reputed multinational corporations, including MSD Pharmaceuticals, Max Bupa, and MetLife India Insurance Co. He has comprehensive knowledge & exposure of Ethics & Compliance policies, practices and processes.
Pfizer is yet to announce a successor for his role.
Pfizer was founded more than 170 years ago.
Pfizer Limited was listed on the Bombay stock exchange in 1966. Today, the company has over one lakh shareholders in India. With annual sales of over Rs. 2,000 crores, it is the fourth largest multinational pharmaceutical company in India. The Company has a portfolio of over 150 products across 15 therapeutic areas.
Its top brands include Prevenar 13, Corex – DX, Dolonex, Enbrel, Becosules and Folvite among others. In addition to its commercial operations, Pfizer Limited also operates a state-of-the-art, award-winning manufacturing facility in Goa that produces more than a billion tablets annually.
The Company specialises with expert therapy in 4 business categories - Vaccines, Hospitals, Internal Medicine and Inflammation and Immunology.
